Notch signaling in hepatocellular carcinoma: molecular targeting in an advanced disease

Abstract

The use of alternative therapeutic approaches in advanced carcinogenesis is a growing investigative base. One such cancer, primary liver cancer, is one of the most commonly occurring cancers worldwide and often presents in late stage disease consequently preventing traditional curative modalities. As a result, hepatocellular carcinoma (HCC), representing the majority of primary liver cancer, is the third most common cause of cancer-related deaths globally. Survival rates are linked to stage of presentation as well as concomitant cirrhosis limiting the 5-year survival in these patients to < 20%. Alternative strategies are in dire need as patients in this cohort have limited palliative options. Currently, sorafenib is the only approved systemic therapy; however, it has a limited survival advantage and low efficacy prompting the empirical need for further evaluation. Understanding of cancer therapy has led to an enhanced focus on the Notch pathway as a potential target for advanced HCC. Notch signaling is a critical component of development and cell fate and has been linked to various modalities including liver regeneration and as a key driver in carcinogenesis. In this review, we will provide a review of the current status of the Notch signaling in liver cancer and of Notch as an alternative potential strategy for advanced HCC.

Keywords

Hepatocellular carcinoma / liver regeneration / Notch inhibitors / Notch signaling / sorafenib

References

[1] European Association For The Study Of The Liver.EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2012;56:908-43

[2] Altekruse SF,Cucinelli JE.Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States..Am J Gastroenterol2014;109:542-53 PMCID:PMC4148914

[3] Llovet JM,Bruix J.Hepatocellular carcinoma..Lancet2003;362:1907-17

[4] Schütte K,Malfertheiner P.Hepatocellular carcinoma – epidemiological trends and risk factors..Dig Dis2009;27:80-92

[5] Siegel R,Zou Z.Cancer statistics, 2014..CA Cancer J Clin2014;64:9-29

[6] McGlynn KA,Hsing AW,Fraumeni JFJr.International trends and patterns of primary liver cancer..Int J Cancer2001;94:290-6

[7] Llovet JM.Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival..Hepatology2003;37:429-42

[8] Bruix J.Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma..Hepatology2005;42:1208-36

[9] Sergio A,Cardin R,Ragazzi R,Girardi L,Burra P,Farinati F.Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness..Am J Gastroenterol2008;103:914-21

[10] Miura JT.Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis..Surg Oncol Clin N Am2015;24:149-66

[11] Pons F,Llovet JM.Staging systems in hepatocellular carcinoma..HPB (Oxford)2005;7:35-41 PMCID:PMC2023920

[12] McGlynn KA.The global epidemiology of hepatocellular carcinoma: present and future..Clin Liver Dis2011;15:223-43, vii PMCID:PMC4141529

[13] Llovet JM,Mazzaferro V,Gane E,de Oliveira AC,Raoul JL,Schwartz M,Zeuzem S,Greten TF,Seitz JF,Haussinger D,Shan M,Voliotis D.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[14] Villanueva A.Targeted therapies for hepatocellular carcinoma..Gastroenterology2011;140:1410-26 PMCID:PMC3682501

[15] Nakanishi K,Yamasaki S,Hirohashi S.Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma..Cancer2005;103:307-12

[16] Vanhaesebroeck B,Hawkins P.PI3K signalling: the path to discovery and understanding..Nat Rev Mol Cell Biol2012;13:195-203

[17] Vivanco I.The phosphatidylinositol 3-Kinase AKT pathway in human cancer..Nat Rev Cancer2002;2:489-501

[18] Lachenmayer A,Savic R,Toffanin S,Villanueva A,Newell P,Barretina J,Ward SC,Mazzaferro V,Friedman SL.Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib..Clin Cancer Res2012;18:4997-5007 PMCID:PMC3446854

[19] Ranganathan P,Capobianco AJ.Notch signalling in solid tumours: a little bit of everything but not all the time..Nat Rev Cancer2011;11:338-51

[20] Razumilava N.Notch-driven carcinogenesis: the merging of hepatocellular cancer and cholangiocarcinoma into a common molecular liver cancer subtype..J Hepatol2013;58:1244-5 PMCID:PMC3818720

[21] Rose SL,Drenzek J.Notch 1 signaling is active in ovarian cancer..Gynecol Oncol2010;117:130-3

[22] Austin J.glp-1 is required in the germ line for regulation of the decision between mitosis and meiosis in C. elegans..Cell1987;51:589-99

[23] Cabrera CV.The generation of cell diversity during early neurogenesis in Drosophila..Development1992;115:893-901

[24] Coffman C,Kintner C.Xotch, the Xenopus homolog of Drosophila notch..Science1990;249:1438-41

[25] Ellisen LW,West DC,Reynolds TC,Sklar J.TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms..Cell1991;66:649-61

[26] Kunnimalaiyaan M.Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors..Oncologist2007;12:535-42

[27] Priess JR,Schnabel R.The glp-1 locus and cellular interactions in early C. elegans embryos..Cell1987;51:601-11

[28] Yamamoto S,Bellen HJ.Introduction to Notch signaling..Methods Mol Biol2014;1187:1-14

[29] Morell CM.Notch signaling and new therapeutic options in liver disease..J Hepatol2014;60:885-90

[30] Mumm JS.Notch signaling: from the outside in..Dev Biol2000;228:151-65

[31] Andersson ER.Therapeutic modulation of Notch signalling – are we there yet?.Nat Rev Drug Discov2014;13:357-78

[32] Allenspach EJ,Aster JC.Notch signaling in cancer..Cancer Biol Ther2002;1:466-76

[33] Fortini ME.Notch signaling: the core pathway and its posttranslational regulation..Dev Cell2009;16:633-47

[34] Geisler F.Emerging roles of Notch signaling in liver disease..Hepatology2015;61:382-92 PMCID:PMC4268103

[35] Gridley T.Notch signaling and inherited disease syndromes..Hum Mol Genet2003;12:R9-13

[36] Strazzabosco M.Notch signaling in hepatocellular carcinoma: guilty in association.Gastroenterology2012;143:1430-4 PMCID:PMC3583012

[37] O'Neil J,Strack P,Tibbitts D,Hardwick J,Meijerink JP,Draetta G,Clurman BE.FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors..J Exp Med2007;204:1813-24 PMCID:PMC2118656

[38] Thompson BJ,Sulis ML,Vilimas T,Ferrando A.The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia..J Exp Med2007;204:1825-35 PMCID:PMC2118676

[39] D'Souza B,Weinmaster G.Canonical and non-canonical Notch ligands..Curr Top Dev Biol2010;92:73-129

[40] Boulter L,Bird TG,Ramachandran P,Ridgway RA,Spee B,Sansom OJ,Lowell S,Forbes SJ.Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease..Nat Med2012;18:572-9 PMCID:PMC3364717

[41] Viatour P,Saddic LA,Andersen JB,Zmoos AF,Schaffer BE,Vogel H,Thorgeirsson SS,Sage J.Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway..J Exp Med2011;208:1963-76 PMCID:PMC3182062

[42] Wu G,George J.Modulation of Notch signaling as a therapeutic approach for liver cancer..Curr Gene Ther2015;15:171-81

[43] Oda T,Pike BL,Krantz ID,Piccoli DA,Spinner NB,Chandrasekharappa SC.Mutations in the human Jagged1 gene are responsible for Alagille syndrome..Nat Genet1997;16:235-42

[44] Li PH,Yang CH,Wen MC.Alagille syndrome with interstitial 20p deletion derived from maternal ins (7;20)..Am J Med Genet1996;63:537-41

[45] Li L,Deng Y,Banta AB,Qi M,Kuo WL,Costa T,Rand EB,Hood L.Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1..Nat Genet1997;16:243-51

[46] McDaniell R,Sanchez-Lara PA,Krantz ID,Spinner NB.NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway..Am J Hum Genet2006;79:169-73 PMCID:PMC1474136

[47] Fausto N,Riehle KJ.Liver regeneration..J Hepatol2012;57:692-4

[48] Riehle KJ,Campbell JS.New concepts in liver regeneration..J Gastroenterol Hepatol2011;26 suppl 1:203-12 PMCID:PMC3077908

[49] Michalopoulos GK.Liver regeneration: alternative epithelial pathways..Int J Biochem Cell Biol2011;43:173-9

[50] Fiorotto R,Morell CM,Scirpo R,Spirli C.Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice..J Hepatol2013;59:124-30 PMCID:PMC3777645

[51] Morell CM,Fabris L.Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis..Clin Res Hepatol Gastroenterol2013;37:447-54

[52] Tanimizu N.Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors..J Cell Sci2004;117:3165-74

[53] Chen Y,Michelotti GA,Swiderska-Syn M,Xie G,Garibaldi F,Suliman HB,Diehl AM.Hedgehog controls hepatic stellate cell fate by regulating metabolism..Gastroenterology2012;143:1319-29 PMCID:PMC3480563

[54] Xie G,Swiderska-Syn M,Krüger L,Premont RT,Diehl AM.Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice..Hepatology2013;58:1801-13 PMCID:PMC3758784

[55] Weng AP,Lee W,Silverman LB,Blacklow SC,Aster JC.Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia..Science2004;306:269-71

[56] van Es JH,Riccio O,Vooijs M,Cozijnsen M,Winton DJ,Clevers H.Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells..Nature2005;435:959-63

[57] Ambros V.Cell cycle-dependent sequencing of cell fate decisions in Caenorhabditis elegans vulva precursor cells..Development1999;126:1947-56

[58] Ridgway J,Wu Y,Liang WC,Kowalski J,Callahan C,Singh M,Tan C,de Sauvage F,Yan M.Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis..Nature2006;444:1083-7

[59] Robinson DR,Wu YM,Cao X,Asangani IA,Maher CA,Lonigro RJ,Siddiqui J,Jing X,Sabel MS,Palanisamy N,Lambros MB,Kumar-Sinha C.Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer..Nat Med2011;17:1646-51 PMCID:PMC3233654

[60] Zender S,Wuestefeld T,Dauch D,El-Khatib M,Bektas H,Gossler A,Plentz R,Malek NP.A critical role for notch signaling in the formation of cholangiocellular carcinomas..Cancer Cell2013;23:784-95

[61] Pickering CR,Yoo SY,Moorthy S,Zhao M,Chang K,Cortez E,Zhang D,Issa JP,Wu X,Weinstein JN,Muzny DM,Wheeler DA,Frederick MJ.Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers..Cancer Discov2013;3:770-81 PMCID:PMC3858325

[62] Cui H,Xu M.Notch3 functions as a tumor suppressor by controlling cellular senescence..Cancer Res2013;73:3451-9

[63] Rahman MT,Rahman M,Katagiri A,Ishikawa M,Nakayama S,Miyazaki K.Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer..Am J Clin Pathol2012;138:535-44

[64] Lu R,Wang H,Bai J.Overexpression of the Notch3 receptor and its ligand Jagged1 in human clinically non-functioning pituitary adenomas..Oncol Lett2013;5:845-51 PMCID:PMC3576212

[65] Greenblatt DY,Jaskula-Sztul R,Haymart M,Chen H.Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells..Oncologist2007;12:942-51

[66] Nakakura EK,Kunnimalaiyaan M,Schuebel KE,Jin N,Nelkin BD,Ball DW.Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling..J Clin Endocrinol Metab2005;90:4350-6

[67] Ning L,Kunnimalaiyaan M.Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells..Oncologist2008;13:98-104

[68] Croquelois A,Terracciano L,Langer I,Heim MH.Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice..Hepatology2005;41:487-96

[69] Giovannini C,Baron Toaldo M,D'Adamo S,Chieco P,Bolondi L.Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma..Oncotarget2013;4:1618-31 PMCID:PMC3858550

[70] Giovannini C,Chieco P,Lago F,Ramazzotti E,Bolondi L.Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism..J Hepatol2009;50:969-79

[71] Gramantieri L,Lanzi A,Ravaioli M,Grazi GL.Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma..Liver Int2007;27:997-1007

[72] Villanueva A,Yanger K,Zong Y,Rodriguez-Carunchio L,Thung S,Llovet JM.Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice..Gastroenterology2012;143:1660-9 PMCID:PMC3505826

[73] Guo X,Sun T,Zou L,Zhang J,Zhao J.Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma..Diagn Pathol2012;7:44 PMCID:PMC3464896

[74] Siemers ER,Kaye J,Porsteinsson A,Zoulnouni P,Holtzman DM,Satterwhite J,Dean RA.Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease..Neurology2006;66:602-4

[75] Espinoza I.Notch inhibitors for cancer treatment..Pharmacol Ther2013;139:95-110 PMCID:PMC3732476

[76] Tammam J,Efferson C,Rao S,Gorenstein J,Kim H,Kunii K,Nikov G,Dai X,Scott M,Bristow L,Reilly JF,Draetta G,Kohl NE,Majumder PK.Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia..Br J Pharmacol2009;158:1183-95 PMCID:PMC2782329

[77] Wei P,Qiu M,Denlinger RH,Tsaparikos K,Hosea N,Randolph S.Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design..Mol Cancer Ther2010;9:1618-28

[78] Aste-Amézaga M,Lineberger JE,Toner TJ,Huang L,Vo KT,Zhao JZ,L'Heureux S,Gordon WR,Andrawes MB,Stegmaier K,Ross KN,Wang H,Chastain M,Audoly LP,Blacklow SC.Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors..PLoS One2010;5:e9094 PMCID:PMC2817004

[79] Wu Y,Choy L,de Leon GP,Finkle D,Wu X,Schahin-Reed D,Shelton A,Watts RJ,Choy R,Kadyk L,Zha J,Hymowitz SG.Therapeutic antibody targeting of individual Notch receptors..Nature2010;464:1052-7

[80] Li K,Wu W,Chang DW,Scoggin S,Vien L,Zheng J,Duensing T,Blacklow SC,Aster JC.Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3..J Biol Chem2008;283:8046-54

[81] Noguera-Troise I,Papadopoulos NJ,Boland P,Lin HC,Thurston G.Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis..Nature2006;444:1032-7

[82] Scehnet JS,Kumar SR,Trindade A,Djokovic D,Ley EJ,Gill PS.Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion..Blood2007;109:4753-60 PMCID:PMC1885521

[83] Funahashi Y,Das I,Huang J,Sharma A,Borisenko V,Suzuki A,Shawber CJ,Yamashiro DJ.A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis..Cancer Res2008;68:4727-35

[84] Small D,Kacer D,Landriscina M,Di Serio C,Maciag T.Soluble Jagged 1 represses the function of its transmembrane form to induce the formation of the Src-dependent chord-like phenotype..J Biol Chem2001;276:32022-30

[85] Mao J,Shi Y,Fan S,Tang J.ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel..Int J Biochem Cell Biol2013;45:1064-73

[86] Zhao N,Zhang M,Zheng Z.Akt-mTOR signaling is involved in Notch-1-mediated glioma cell survival and proliferation..Oncol Rep2010;23:1443-7

[87] Sun Q,Wang Y,Wang P.Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma..Oncol Rep2014;31:933-9

[88] Wang F,Wang J,Luo J.Notch1 signaling contributes to the oncogenic effect of HBx on human hepatic cells..Biotechnol Lett2013;35:29-37

[89] Gramantieri L,Callegari E,Lanza G,Bolondi L.MicroRNA involvement in hepatocellular carcinoma..J Cell Mol Med2008;12:2189-204 PMCID:PMC4514099

[90] Lujambio A.The microcosmos of cancer..Nature2012;482:347-55 PMCID:PMC3509753

[91] Xu Y,Ma L,Shen J,Liu J,Bian X,Qian C.MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest..Cancer Lett2011;310:160-9

[92] Bai S,Wang B,Datta J,Yadav A,Kumar P.MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib..J Biol Chem2009;284:32015-27 PMCID:PMC2797273

[93] Wang Y,Ma JZ,Ren J,Tantoso E,Ooi LL,Lee CG.Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target..J Biol Chem2008;283:13205-15

[94] Gyöngyösi B B,Járay B,Fassan M,Schaff Z.Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma..J Histochem Cytochem2014;62:547-55